Locus Ceruleus Degeneration Promotes Alzheimer Pathogenesis in Amyloid Precursor Protein 23 Transgenic Mice

Locus ceruleus (LC) degeneration and loss of cortical noradrenergic innervation occur early in Alzheimer’s disease (AD). Although this has been known for several decades, the contribution of LC degeneration to AD pathogenesis remains unclear. We induced LC degeneration with N-(2-chloroethyl)-N-ethyl-bromo-benzylamine (dsp4) in amyloid precursor protein 23 (APP23) transgenic mice with a low amyloid load. Then 6 months later the LC projection areas showed a robust elevation of glial inflammation along with augmented amyloid plaque deposits. Moreover, neurodegeneration and neuronal loss significantly increased. Importantly, the paraventricular thalamus, a nonprojection area, remained unaffected. Radial arm maze and social partner recognition tests revealed increased memory deficits while high-resolution magnetic resonance imaging-guided micro-positron emission tomography demonstrated reduced cerebral glucose metabolism, disturbed neuronal integrity, and attenuated acetylcholinesterase activity. Nontransgenic mice with LC degeneration were devoid of these alterations. Our data demonstrate that the degeneration of LC affects morphology, metabolism, and function of amyloid plaque-containing higher brain regions in APP23 mice. We postulate that LC degeneration substantially contributes to AD development.

[1]  W. Heiss,et al.  Early detection of irreversibly damaged ischemic tissue by flumazenil positron emission tomography in cats. , 1997, Stroke.

[2]  M. Esiri,et al.  Noradrenergic changes, aggressive behavior, and cognition in patients with dementia , 2002, Biological Psychiatry.

[3]  B. Sommer,et al.  Neuron loss in APP transgenic mice , 1998, Nature.

[4]  F. Bloom,et al.  Nucleus locus ceruleus: new evidence of anatomical and physiological specificity. , 1983, Physiological reviews.

[5]  J. Harro,et al.  Dose-dependent effects of noradrenergic denervation by DSP-4 treatment on forced swimming and β-adrenoceptor binding in the rat , 1999, Journal of Neural Transmission.

[6]  P. Yates,et al.  Changes in the Monoamine Containing Neurones of the Human Cns in Senile Dementia , 1980, British Journal of Psychiatry.

[7]  M. Roth,et al.  NEURONAL DEGENERATION IN LOCUS CERULEUS AND CORTICAL CORRELATES OF ALZHEIMER DISEASE , 1987, Alzheimer disease and associated disorders.

[8]  B. Sommer,et al.  Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[9]  M. Staufenbiel,et al.  Expression of endothelial and inducible NOS-isoforms is increased in Alzheimer’s disease, in APP23 transgenic mice and after experimental brain lesion in rat: evidence for an induction by amyloid pathology , 2001, Brain Research.

[10]  D. Johnston,et al.  Noradrenergic enhancement of long-term potentiation at mossy fiber synapses in the hippocampus. , 1988, Journal of neurophysiology.

[11]  D. Feinstein,et al.  Noradrenergic regulation of inflammatory gene expression in brain , 2002, Neurochemistry International.

[12]  J. Kiernan,et al.  A histochemical examination of the staining of kainate-induced neuronal degeneration by anionic dyes. , 1998, Biotechnic & histochemistry : official publication of the Biological Stain Commission.

[13]  T. Bliss,et al.  Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice , 1999, Nature Neuroscience.

[14]  J S Beckman,et al.  Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. , 1996, The American journal of physiology.

[15]  Wade K. Smith,et al.  Disease‐specific patterns of locus coeruleus cell loss , 1992, Annals of neurology.

[16]  A. Levey,et al.  Choline acetyltransferase immunoreactivity in the rat thalamus , 1987, The Journal of comparative neurology.

[17]  A. Cuello,et al.  A nerve growth factor mimetic TrkA antagonist causes withdrawal of cortical cholinergic boutons in the adult rat. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[18]  R. Malinow,et al.  APP Processing and Synaptic Function , 2003, Neuron.

[19]  P. Nisen,et al.  Inhibition of lipopolysaccharide-induced IL-1 beta transcription by cyclic adenosine monophosphate in human astrocytic cells. , 1995, Journal of immunology.

[20]  C. Marsden,et al.  Effects of central noradrenaline depletion by the selective neurotoxin DSP-4 on the behaviour of the isolated rat in the elevated plus maze and water maze , 2001, Psychopharmacology.

[21]  Thomas Klockgether,et al.  Nonsteroidal Anti-Inflammatory Drugs and Peroxisome Proliferator-Activated Receptor-γ Agonists Modulate Immunostimulated Processing of Amyloid Precursor Protein through Regulation of β-Secretase , 2003, The Journal of Neuroscience.

[22]  B. Winblad,et al.  Changes in the Brain Catecholamines in Patients with Dementia of Alzheimer Type , 1979, British Journal of Psychiatry.

[23]  C. Kahn,et al.  Role for neuronal insulin resistance in neurodegenerative diseases , 2004 .

[24]  R. Levy,et al.  Disproportionate loss of noradrenergic and cholinergic neurons as cause of depression in Alzheimer's disease--a hypothesis. , 1994, Pharmacopsychiatry.

[25]  M. Staufenbiel,et al.  Amyloid-Associated Neuron Loss and Gliogenesis in the Neocortex of Amyloid Precursor Protein Transgenic Mice , 2002, The Journal of Neuroscience.

[26]  K. Duff,et al.  Reorganization of Cholinergic Terminals in the Cerebral Cortex and Hippocampus in Transgenic Mice Carrying Mutated Presenilin-1 and Amyloid Precursor Protein Transgenes , 1999, The Journal of Neuroscience.

[27]  K. Herrup,et al.  Ectopic Cell Cycle Proteins Predict the Sites of Neuronal Cell Death in Alzheimer’s Disease Brain , 1998, The Journal of Neuroscience.

[28]  S. van den Noort,et al.  Norepinephrine inhibits gamma-interferon-induced major histocompatibility class II (Ia) antigen expression on cultured astrocytes via beta-2-adrenergic signal transduction mechanisms. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[29]  M. Lynch,et al.  Evidence That Increased Hippocampal Expression of the Cytokine Interleukin-1β Is a Common Trigger for Age- and Stress-Induced Impairments in Long-Term Potentiation , 1998, The Journal of Neuroscience.

[30]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[31]  T. Hartmann,et al.  TNFα plus IFNγ induce the production of Alzheimer β‐amyloid peptides and decrease the secretion of APPs , 1999 .

[32]  Joseph S. Beckman,et al.  Widespread Peroxynitrite-Mediated Damage in Alzheimer’s Disease , 1997, The Journal of Neuroscience.

[33]  M. Sporn,et al.  Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease , 1996, The Journal of experimental medicine.

[34]  S. Thomas,et al.  A Distinct Role for Norepinephrine in Memory Retrieval , 2004, Cell.

[35]  K. Jellinger.  Pathology of Parkinsonism , 2000, Neurobiology of Aging.

[36]  David S. Olton,et al.  The radial arm maze as a tool in behavioral pharmacology , 1987, Physiology & Behavior.

[37]  Y. Izumi,et al.  Norepinephrine promotes long‐term potentiation in the adult rat hippocampus in vitro , 1999, Synapse.

[38]  Chris Zarow,et al.  Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. , 2003, Archives of neurology.

[39]  et al.,et al.  Discrimination between Alzheimer Dementia and Controls by Automated Analysis of Multicenter FDG PET , 2002, NeuroImage.

[40]  T. Klockgether,et al.  Noradrenergic Depletion Potentiates β-Amyloid-Induced Cortical Inflammation: Implications for Alzheimer's Disease , 2002, The Journal of Neuroscience.

[41]  H. Lahtinen,et al.  Spatial Learning and Noradrenaline Content in the Brain and Periphery of Young and Aged Rats , 1994, Experimental Neurology.

[42]  R. Anwyl,et al.  β-Amyloid-Mediated Inhibition of NMDA Receptor-Dependent Long-Term Potentiation Induction Involves Activation of Microglia and Stimulation of Inducible Nitric Oxide Synthase and Superoxide , 2004, The Journal of Neuroscience.

[43]  Hitoshi Shinotoh,et al.  Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease , 1997, The Lancet.

[44]  A. Cho,et al.  The interaction of the beta-haloethyl benzylamines, xylamine, and DSP-4 with catecholaminergic neurons. , 1990, Annual review of pharmacology and toxicology.

[45]  A. Rosenquist,et al.  Noradrenergic mechanisms in neurodegenerative diseases: a theory , 2004, Brain Research Reviews.

[46]  L. Bezin,et al.  Quantitative study of tyrosine hydroxylase protein levels within the somatic area of the rat locus coeruleus during postnatal development , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[47]  C. Brosnan,et al.  The effect of norepinephrine on endotoxin-mediated macrophage activation , 1991, Journal of Neuroimmunology.

[48]  Benjamin J. Shannon,et al.  Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory , 2005, The Journal of Neuroscience.

[49]  J. Sarvey,et al.  Norepinephrine regulates long-term potentiation of both the population spike and dendritic EPSP in hippocampal dentate gyrus , 1987, Brain Research Bulletin.

[50]  J. Fritschy,et al.  Immunohistochemical analysis of the neurotoxic effects of DSP-4 identifies two populations of noradrenergic axon terminals , 1989, Neuroscience.

[51]  M. Ohno,et al.  Noradrenergic DSP-4 Lesions Aggravate Impairment of Working Memory Produced by Hippocampal Muscarinic Blockade in Rats , 1997, Pharmacology Biochemistry and Behavior.

[52]  P. Kelly,et al.  Cholinergic Changes in the APP23 Transgenic Mouse Model of Cerebral Amyloidosis , 2002, The Journal of Neuroscience.